Rule Summary and Fiscal Analysis
Part A - General Questions

Rule Number: 4123-6-21.6

Rule Type: Amendment

Rule Title/Tagline: `First fill of outpatient medications.

Agency Name: Bureau of Workers' Compensation

Division:

Address: 30 West Spring Street Columbus OH 43215

Contact: Eva Dixon **Phone:** 614-644-8346

Email: Eva.d.2@bwc.ohio.gov

I. Rule Summary

1. **Is this a five year rule review?** No

    A. **What is the rule's five year review date?** 5/1/2025

2. **Is this rule the result of recent legislation?** No

3. **What statute is this rule being promulgated under?** 119.03

4. **What statute(s) grant rule writing authority?** 4121.12, 4121.121, 4121.30, 4121.31, 4121.44, 4121.441, 4123.05, 4123.34, 4123.66

5. **What statute(s) does the rule implement or amplify?** 4121.12, 4121.121, 4121.44, 4121.441, 4123.66

6. **Does the rule implement a federal law or rule in a manner that is more stringent or burdensome than the federal law or regulation requires?** No

    A. **If so, what is the citation to the federal law or rule?** Not Applicable

7. **What are the reasons for proposing the rule?**

    The rule is revised for a grammatical error in the title, and to update the list of medications in the appendix to the rule that may be reimbursed as a first fill medication when medically necessary. The rule implements Ohio Revised Code 4123.66(B).

8. **Summarize the rule's content, and if this is an amended rule, also summarize the rule's changes.**

   This rule explains the circumstances under which the Bureau reimburses for the first fill of prescription drugs, for medical conditions identified in an application for workers' compensation or benefits, prior to the date the Bureau issues an initial claim determination order. The proposed changes include

   MEDICATIONS TO BE ADDED TO THE FIRST FILL FORMULARY
   - Baclofen Tab 5 MG, quantity limit 42
   - Baclofen Tab 10 MG quantity limit 42
   - Emtricitabine Cap 200 MG, quantity limit 30
   - Etravirine Tab 200 MG, quantity limit 60
   - Methocarbamol Tab 750 MG, quantity limit 42
   - Rilpivirine Tab 25 MG, quantity limit 30

   MEDICATIONS TO BE REMOVED FROM THE FORMULARY
   - Indinavir Sulfate Cap 400 MG
   - Nelfinavir Mesylate Tab 625 MG

9. **Does the rule incorporate material by reference?** No

10. **If the rule incorporates material by reference and the agency claims the material is exempt pursuant to R.C. 121.75, please explain the basis for the exemption and how an individual can find the referenced material.**

    Not Applicable

11. **If revising or re-filing the rule, please indicate the changes made in the revised or re-filed version of the rule.**

    Not Applicable

II. Fiscal Analysis

12. **Please estimate the increase / decrease in the agency's revenues or expenditures in the current biennium due to this rule.**

    This will have no impact on revenues or expenditures.

    $0.00

No fiscal effects expected on current or future budgets.

13. **What are the estimated costs of compliance for all persons and/or organizations directly affected by the rule?**

    This rule only affects injured workers receiving prescription benefits from the Bureau.

14. **Does the rule increase local government costs? (If yes, you must complete an RSFA Part B).** No

15. **Does the rule regulate environmental protection? (If yes, you must complete an RSFA Part C).** No

16. **If the rule imposes a regulation fee, explain how the fee directly relates to your agency's cost in regulating the individual or business.**

    Not Applicable.

III. Common Sense Initiative (CSI) Questions

17. **Was this rule filed with the Common Sense Initiative Office?** Yes

18. **Does this rule have an adverse impact on business?** Yes

    A. **Does this rule require a license, permit, or any other prior authorization to engage in or operate a line of business?** No

    B. **Does this rule impose a criminal penalty, a civil penalty, or another sanction, or create a cause of action, for failure to comply with its terms?** No

    C. **Does this rule require specific expenditures or the report of information as a condition of compliance?** Yes

       Prescribers have to indicate the first fill prescription is for a work-related injury for payment of first fill medications.

    D. **Is it likely that the rule will directly reduce the revenue or increase the expenses of the lines of business of which it will apply or applies?** No

IV. Regulatory Restriction Requirements under S.B. 9. Note: This section only applies to agencies described in R.C. 121.95(A).

19. Are you adding a new or removing an existing regulatory restriction as defined in R.C. 121.95? No

A. How many new regulatory restrictions do you propose adding to this rule?

Not Applicable

B. How many existing regulatory restrictions do you propose removing from this rule?

Not Applicable

C. If you are not removing existing regulatory restrictions from this rule, please list the rule number(s) from which you are removing restrictions.

Not Applicable

D. Please justify the adoption of the new regulatory restriction(s).

Not Applicable